Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05816226 · ClinicalTrials.gov registry record · Phase 3
Topical Treatment for TMJ Arthralgia
A Phase 3 study of TMJ Pain, sponsored by University of the Pacific.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT05816226: Recruiting Phase 3 study of TMJ Pain, sponsored by University of the Pacific.
NCT05816226 is a Phase 3 study of TMJ Pain that is actively recruiting participants, run by University of the Pacific. The registered enrollment target is 90 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05816226, a Phase 3 study of TMJ Pain, is actively recruiting participants, sponsored by University of the Pacific.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are: * How does pain reduction compare? * How does improvement in jaw function limitation compare? * How do side effects compare? Participants will * On day 1 be examined and report their pain level and jaw function limitation * On days 1-21, apply their cream four times a day * On day 21, report their pain level, jaw function limitation, compliance with instructions, and side effects. Researchers will compare topical 2.5% hydrocortisone and topical 1% diclofenac to see if efficacy and side effects differ.
Primary Outcome
Using Visual Analog Scale, Range 0 - 10 cm, with 0 cm = no pain, and 10 cm = extreme pain
Conditions Studied
Interventions
- DRUG Hydrocortisone 2.5%
- DRUG Diclofenac 1% topical
Study Locations (1)
California
- Arthur A. Dugoni School of Dentistry, University of the Pacific - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
What NCT05816226 shows while recruiting
NCT05816226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with TMJ Pain appearing as the primary indexed condition, and to 2 interventions - of which Hydrocortisone 2.5% is the first listed.
NCT05816226 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05816226 about?
NCT05816226 is a clinical study titled "Topical Treatment for TMJ Arthralgia". The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are: * How does pain reduction compare? * How does improvement in jaw function limitation compare? * How do side effects compare? Participants will * On...
What is the current status of trial NCT05816226?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2023-06-01. Estimated completion is 2026-04.
What conditions does trial NCT05816226 study?
This clinical trial studies the following conditions: TMJ Pain.
What interventions are being tested in trial NCT05816226?
The interventions under investigation include: Hydrocortisone 2.5% (DRUG), Diclofenac 1% topical (DRUG).
Who is sponsoring clinical trial NCT05816226?
This trial is sponsored by University of the Pacific, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05816226 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05816226's enrollment target sits among peer trials
90 1725th of 2000 higher than 263 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI